BLOCK BIOSCIENCES
Intercepting the
spread of cancers to the brain
Shifting from Reaction to Prevention
At Block Biosciences, we are developing first-in-class therapeutics designed to intercept the spread of cancer to the brain.
Addressing a targetable vulnerability
We've identified and are inhibiting a key step in the purine biosynthesis pathway, which is essential for cancer cells to initiate brain metastases.
Guided by clinically-validated models
Our drug discovery is powered by a unique library of clinically-relevant models, specifically developed to study brain metastasis.
Building a brighter future
Our technology has the potential to reduce the risk of forming a secondary brain metastasis, one of the deadliest forms of brain cancer.
Our Technology
We leverage clinically-validated models and a deep understanding of metastatic biology to design precision therapeutics.
Our technology platforms are designed to accelerate research, enhance diagnostics, and bring novel therapies to fruition.
Our focus is on creating advancements that have the potential to revolutionize healthcare and enable more patients to not only survive cancer but to reclaim their futures.
Our Team
Amie Phinney, PhD, MBA
Co-Founder and CEO
Mathew Piotrowski, PhD
Co-Founder and Senior Scientist
Sheila Singh, MD, PhD, FRSC
Co-Founder and CSO
Lauren Irwin, PhD
Senior Scientist
Jakob Magolan, PhD
Co-Founder and Head of Chemistry
Samantha Poon
IT & Communications Specialist
Agata Kieliszek, PhD
Co-Founder and Head of Biology and Operations
Meet The
Experts
News & Media
Follow our progress. Here you'll find announcements on our research breakthroughs, leadership developments, and key industry recognition as we advance our therapeutic pipeline.
Made Possible Through Collaboration With
